ASCENDIS PHARMA A/S: Financial statements 2020
CVR: 29918791
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
ASCENDIS PHARMA A/S (CVR 29918791) has filed annual accounts for 2020. In 2020, the company reported revenue of EUR 6,953,000 and a net result of EUR -418,955,000 compared with EUR -218,016,000 the year before. That is a decrease of 48% compared with the year before. The profit margin was -6,025.5%. Equity in the 2020 report amounted to EUR 838,711,000. The solvency ratio was 85.6%.
- Revenue
- EUR 6,953,000
- Profit/Loss
- EUR -418,955,000
- Equity
- EUR 838,711,000
- Total Assets
- EUR 979,793,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | 7 mio. EUR | - | -419 mio. EUR | 838.7 mio. EUR | - |
| 2019 | 13.4 mio. EUR | - | -218 mio. EUR | 597.1 mio. EUR | - |
| 2018 | 10.6 mio. EUR | - | -130.1 mio. EUR | 280.1 mio. EUR | - |
| 2017 | 1.5 mio. EUR | - | -123.9 mio. EUR | 187.2 mio. EUR | - |
| 2016 | 4.6 mio. EUR | - | -68.5 mio. EUR | 176.6 mio. EUR | - |
Official annual report
How creditworthy is ASCENDIS PHARMA A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
ASCENDIS PHARMA A/S has published its annual report for 2019. Revenue came to DKK 13,375,000, and the net result was DKK -218,016,000.
About ASCENDIS PHARMA A/S
ASCENDIS PHARMA A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2006. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA ApS and CADENZA PARTNERS ApS. The management consists of Jan Møller Mikkelsen, Anni Lotte Kirstine Pedersen and Michael Wolff Jensen. The board consists of Albert Cha (chair), Jan Møller Mikkelsen, Jean-Jacques Bienaime and Lars Holtug. The company is owned by Cede & Co. The company has 688 employees (2026). In 2025, the company reported revenue of EUR 720,132,000 and a net result of EUR -228,034,000 compared with EUR -378,084,000 the year before. Equity in the 2025 report amounted to EUR -162,821,000.